InMed Pharmaceuticals Inc (INM)

[LS64]

For 2018 my expectations are pretty limited for InMed. 90+ cannabinoid patent will take time, building the scaled up manufacture will take time and so will the deployment of phase 1 for their EB drug.

For 2018 my hope is their stock to go back to 0.40 or even less so I can backup the truck and load some more at will during the year.

This stock is one or two major news away from leaving the launch pad after which it will be much much more expensive to take or increase a position on.

For quicker potential for explosive growth for 2018 there are other candidates in the cannabis space: Aurora, Canopy Growth and Lexaria to name a few.

With InMed I think we all agree patience will be rewarded handsomely. Shorters, please help yourself and make InMed cheaper so in due time I can retire earlier and stop working for idiots !